A Phase 1 interventional study of MK-8527 and Probenecid in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Researchers are studying a medicine called MK-8527 to learn how it behaves in the body of healthy adults.
The goal of this study is to learn about the effect of MK-8527 when it is taken with food or with other medicines. Researchers also want to learn about the safety of MK-8527 and if people tolerate it. Tolerate means participants will receive treatment in the trial unless they need to stop it due to health problems.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single dose of MK-8527 with food and a single dose of MK-8527 without food.
Drug: MK-8527
Participants will receive a single dose of MK-8527 alone and a single dose of MK-8527 in combination with probenecid.
Drug: MK-8527 · Drug: Probenecid
Participants will receive a single dose of MK-8527 alone and a single dose of MK-8527 in combination with itraconazole.
Drug: MK-8527 · Drug: Itraconazole
Oral tablet
Oral tablet
Oral solution
Part 1: Area Under the Concentration Time Curve From Time 0 to Infinity (AUC0-inf) of MK-8527 in Plasma With and Without Food
Blood samples will be collected at multiple time points to estimate AUC0-inf of MK-8527 in plasma.
Time frame: Predose and at designated timepoints (up to 336 hours postdose)
Part 2: AUC0-inf of MK-8527 in Plasma With and Without Probenecid
Blood samples will be collected at multiple time points to estimate AUC0-inf of MK-8527 in plasma.
Time frame: Predose and at designated timepoints (up to 336 hours postdose)
Part 3: AUC0-inf of MK-8527 in Plasma With and Without Itraconazole
Blood samples will be collected at multiple time points to estimate AUC0-inf of MK-8527 in plasma.
Time frame: Predose and at designated timepoints (up to 336 hours postdose)
Part 1: Area Under the Concentration Time Curve From Time 0 to 336 Hours (AUC0-336) of MK-8527 in Plasma With and Without Food
Blood samples will be collected at multiple time points to estimate AUC0-336 of MK-8527 in plasma.
Time frame: Predose and at designated timepoints (up to 336 hours postdose)
Part 1: Time to Maximum Plasma Concentration (Tmax) of MK-8527 in Plasma With and Without Food
Blood samples will be collected to estimate the Tmax of MK-8527 in plasma.
Time frame: Predose and at designated timepoints (up to 336 hours postdose)
Part 1: Maximum Plasma Concentration (Cmax) of MK-8527 in Plasma With and Without Food
Blood samples will be collected to estimate the Cmax of MK-8527 in plasma.
Time frame: Predose and at designated timepoints (up to 336 hours postdose)
Part 1: Apparent Terminal Half-life (t1/2) of MK-8527 in Plasma With and Without Food
Blood samples will be collected to estimate the apparent terminal t1/2 of MK-8527 in plasma.
Time frame: Predose and at designated timepoints (up to 336 hours postdose)
Part 1: Number of Participants Who Experience an Adverse Event (AE)
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience AE will be reported.
Time frame: Up to approximately 43 days
Part 1: Number of Participants Who Discontinue Study Treatment Due to an AE
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be reported.
Time frame: Up to approximately 43 days
Part 2: AUC0-336 of MK-8527 in Plasma With and Without Probenecid
Blood samples will be collected to estimate the AUC0-336 of MK-8527 in plasma.
Time frame: Predose and at designated timepoints (up to 336 hours postdose)
Part 2: Tmax of MK-8527 in Plasma with and without Probenecid
Blood samples will be collected to estimate the Tmax of MK-8527 in plasma.
Time frame: Predose and at designated timepoints (up to 336 hours postdose)
Part 2: Cmax of MK-8527 in Plasma With and Without Probenecid
Blood samples will be collected to estimate the Cmax of MK-8527 in plasma.
Time frame: Predose and at designated timepoints (up to 336 hours postdose)
Part 2: Apparent Terminal t1/2 of MK-8527 in Plasma With and Without Probenecid
Blood samples will be collected to estimate the apparent terminal t1/2 of MK-8527 in plasma.
Time frame: Predose and at designated timepoints (up to 336 hours postdose)
Part 2: Urine Concentration at 72 Hours of MK-8527
Urine samples will be collected to estimate the urine concentration of MK-8527.
Time frame: At designated timepoints (up to 72 hours postdose)
Part 2: Renal Clearance of MK-8527
Urine samples will be collected to estimate the renal clearance of MK-8527.
Time frame: At designated timepoints (up to 72 hours postdose)
Part 2: Number of Participants Who Experience an AE
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience AE will be reported.
Time frame: Up to approximately 43 days
Part 2: Number of Participants Who Discontinue Study Treatment Due to an AE
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be reported.
Time frame: Up to approximately 43 days
Part 3: AUC0-336 of MK-8527 in Plasma With and Without Itraconazole
Blood samples will be collected at multiple time points to estimate AUC0-336 of MK-8527 in plasma.
Time frame: Predose and at designated timepoints (up to 336 hours postdose)
Part 3: Tmax of MK-8527 in Plasma With and Without Itraconazole
Blood samples will be collected to estimate the Tmax of MK-8527 in plasma.
Time frame: Predose and at designated timepoints (up to 336 hours postdose)
Part 3: Cmax of MK-8527 in Plasma With and Without Itraconazole
Blood samples will be collected to estimate the Cmax of MK-8527 in plasma.
Time frame: Predose and at designated timepoints (up to 336 hours postdose)
Part 3: Apparent Terminal t1/2 of MK-8527 in Plasma With and Without Itraconazole
Blood samples will be collected to estimate the apparent t1/2 of MK-8527 in plasma.
Time frame: Predose and at designated timepoints (up to 336 hours postdose)
Part 3: Urine Concentration at 72 Hours of MK-8527
Urine samples will be collected to estimate the urine concentration of MK-8527.
Time frame: At designated timepoints (up to 72 hours postdose)
Part 3: Renal Clearance of MK-8527
Urine samples will be collected to estimate the renal clearance of MK-8527.
Time frame: At designated timepoints (up to 72 hours postdose)
Part 3: Number of Participants Who Experience an AE
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience AE will be reported.
Time frame: Up to approximately 43 days
Part 3: Number of Participants Who Discontinue Study Treatment Due to an AE
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be reported.
Time frame: Up to approximately 43 days
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Jun 2026 to primary completion in Oct 2026, 3 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alimatravir